Third Strike For Novartis: DOJ Alleges Firm Paid Kickbacks To Specialty Pharmacies
This article was originally published in The Pink Sheet Daily
Executive Summary
Government has intervened in a whistleblower suit alleging Novartis provided financial incentives to CVS Caremark and other specialty pharmacies to get them to recommend Exjade, Gleevec, and other Novartis drugs.
You may also be interested in...
Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review
HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.